Meg Jardine's Publications

• Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY

  Journal articles

  2020

  Diabetes, Obesity and Metabolism

• Examining outcomes in chronic disease in the 45 and up study (the EXTEnD45 study): Protocol for an Australian linked cohort study

  Journal articles

  2020

  JMIR Research Protocols

• CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS

  Conference Abstracts

  2020

  JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

• EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

  Conference Abstracts

  2020

  JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

• EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

  Conference Abstracts

  2020

  JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

• EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

  Conference Posters

  2020

• Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

  Journal articles

  2020

  Journal of the American Heart Association

• Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

  Journal articles

  2020

  Circulation

• Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

  Conference Papers

  2020

  Kidney International

• Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Sex Differences in CKD Prevalence in Asia: A Systematic Review and Meta-Analysis

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial

  Journal articles

  2020

  Journal of the American Society of Nephrology

• SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS

  Journal articles

  2020

  Kidney International Reports

• SUN-119 COMPARING SURVIVAL IN PATIENTS WITHCHRONIC KIDNEY DISEASE ACROSS THREE COUNTRIES - RESULTS FROM THE STUDY OF HEART AND RENAL PROTECTION-EXTENDED REVIEW (SHARP-ER)

  Conference Abstracts

  2020

  Kidney International Reports

• THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

  Journal articles

  2020

  Journal of the American College of Cardiology

• SUN-161 CIRCULATING AUTOANTIBODIES TOERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES

  Journal articles

  2020

  Kidney International Reports

• Varying association of extended hours dialysis with quality of life

  Journal articles

  2019

  Clinical Journal of the American Society of Nephrology

• Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c 7%: Results From the CREDENCE Trial

  Conference Papers

  2019

  CIRCULATION

• Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

  Journal articles

  2019

  BMJ Global Health

• SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

  Journal articles

  2019

  The Lancet Diabetes and Endocrinology